FANCONI-TAF (FANTA) study

  • Research type

    Research Study

  • Full title

    Safety of tenofovir alafenamide (TAF) in patients with a history of tubulopathy on tenofovir disoproxil fumarate (TDF)

  • IRAS ID

    211705

  • Contact name

    Frank Post

  • Contact email

    frank.post@kcl.ac.uk

  • Sponsor organisation

    Kings College Hospital

  • Eudract number

    2016-003345-29

  • Duration of Study in the UK

    3 years, 0 months, 0 days

  • Research summary

    Summary of Research
    Patients with a history of renal disorder on tenofovir disoproxil fumarate (TDF) are typically managed on TDF-sparing regimens with increased pill burden, suboptimal HIV/hepatitis B activity and potential adverse effects. A new formulation of tenofovir (Tenofovir alafenamide, TAF) was recently licensed and has a much improved renal safety profile. We wish to examine the safety of TAF in patients with a history of tubulopathy (a specific type of kidney injury) on TDF. We propose to conduct a clinical trial to examine the safety of TAF under careful monitoring of kidney function and with evaluation of bone mineral density. If the renal/bone safety of TAF is confirmed in patients with a history of renal disorder, many could switch to more convenient, better tolerated or more broadly active antiretroviral therapy regimens. It would also inform renal monitoring strategies for patients on TAF-based medications in clinical practice.

    Summary of Results
    The purpose of the FANTA Study was to evaluate the effects of tenofovir alafenamide (TAF) on kidneys and bone in patients with a history of tubulopathy and FANCONI syndrome while receiving the antiretroviral medication tenofovir disoproxil fumarate (TDF). In summary, 31 patients with well-controlled HIV were enrolled and followed up for a duration of 5 years. The study results revealed that kidney function and bone turnover remained stable and no cases of recurrent tubulopathy were encountered, indicating that TAF is a safe, well-tolerated and effective treatment for individuals with HIV who experienced tubulopathy when taking TDF.

  • REC name

    London - Dulwich Research Ethics Committee

  • REC reference

    16/LO/1812

  • Date of REC Opinion

    14 Oct 2016

  • REC opinion

    Favourable Opinion